Kos Parmaceuticals News
Most Popular Kos Parmaceuticals Story
Biotech entrepreneur turns talents to venture fund
The Wall Street Journal offers an in-depth look at Michael Jaharis, a noted biotech entrepreneur who recently sold Kos Pharmaceuticals to Abbott for $4.2 billion. Jaharis has launched Vatera Capital, Read more...
Latest Headlines
- March 29, 2011
- August 15, 2007
- November 8, 2006
- November 5, 2006
- September 21, 2006
- December 15, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
